Tackling the Cardio-Kidney-Metabolic Burden in Cancer.

IF 5.2 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Atherosclerosis Reports Pub Date : 2025-09-15 DOI:10.1007/s11883-025-01336-5

Tarek Nahle, Viraj Shah, Harikrishnan Hyma Kunhiraman, Omar M Makram, Ola Ahmed, Sandeep Yerraguntla, Gaurav Gopu, Jenny Vy, Shivam Singh, Tanvi Borse, Kevin Kalinsky, Anita Deswal, Diego Sadler, Vipul Chitalia, Neal L Weintraub, Avirup Guha

{"title":"Tackling the Cardio-Kidney-Metabolic Burden in Cancer.","authors":"Tarek Nahle, Viraj Shah, Harikrishnan Hyma Kunhiraman, Omar M Makram, Ola Ahmed, Sandeep Yerraguntla, Gaurav Gopu, Jenny Vy, Shivam Singh, Tanvi Borse, Kevin Kalinsky, Anita Deswal, Diego Sadler, Vipul Chitalia, Neal L Weintraub, Avirup Guha","doi":"10.1007/s11883-025-01336-5","DOIUrl":null,"url":null,"abstract":"Purpose of the review: This review aims to examine the clinical relevance of cardio-kidney-metabolic syndrome (CKMS) in oncology, highlighting its role as both a preexisting comorbidity and a consequence of cancer treatment. It aims to integrating CKMS staging into personalized cancer care.Recent findings: CKMS is a progressive syndrome marked by dysfunction across cardiovascular, renal, and metabolic systems. Cancer therapies-particularly hormonal agents, immune checkpoint inhibitors, and chemotherapeutics-can accelerate or reveal underlying CKMS through inflammatory and metabolic pathways. Early risk stratification based on CKMS stage enables more effective monitoring, referral, and therapeutic strategies. A stage-based, multidisciplinary approach tailored to cancer type and comorbidity burden is essential for optimizing outcomes. With rising multimorbidity among cancer patients, recognizing and addressing CKMS is increasingly critical. Routine CKMS assessment in oncology offers a pathway for earlier intervention and potentially altering its course. A comprehensive, individualized care model based on CKS stage is necessary to mitigate CKMS-related complications and deliver high-quality, integrated cancer care.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"92"},"PeriodicalIF":5.2000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Atherosclerosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11883-025-01336-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of the review: This review aims to examine the clinical relevance of cardio-kidney-metabolic syndrome (CKMS) in oncology, highlighting its role as both a preexisting comorbidity and a consequence of cancer treatment. It aims to integrating CKMS staging into personalized cancer care.

Recent findings: CKMS is a progressive syndrome marked by dysfunction across cardiovascular, renal, and metabolic systems. Cancer therapies-particularly hormonal agents, immune checkpoint inhibitors, and chemotherapeutics-can accelerate or reveal underlying CKMS through inflammatory and metabolic pathways. Early risk stratification based on CKMS stage enables more effective monitoring, referral, and therapeutic strategies. A stage-based, multidisciplinary approach tailored to cancer type and comorbidity burden is essential for optimizing outcomes. With rising multimorbidity among cancer patients, recognizing and addressing CKMS is increasingly critical. Routine CKMS assessment in oncology offers a pathway for earlier intervention and potentially altering its course. A comprehensive, individualized care model based on CKS stage is necessary to mitigate CKMS-related complications and deliver high-quality, integrated cancer care.

查看原文本刊更多论文

解决癌症的心脏-肾脏-代谢负担。

综述目的：本综述旨在探讨心肾代谢综合征（CKMS）在肿瘤学中的临床相关性，强调其作为既存在的合并症和癌症治疗的结果的作用。它旨在将CKMS分期纳入个性化的癌症治疗。最近发现：CKMS是一种进行性综合征，以心血管、肾脏和代谢系统功能障碍为特征。癌症治疗——尤其是激素制剂、免疫检查点抑制剂和化疗——可以通过炎症和代谢途径加速或揭示潜在的CKMS。基于CKMS分期的早期风险分层可以实现更有效的监测、转诊和治疗策略。针对癌症类型和合并症负担量身定制的基于阶段的多学科方法对于优化结果至关重要。随着癌症患者多发病的增加，认识和解决CKMS变得越来越重要。肿瘤常规CKMS评估为早期干预和潜在改变其进程提供了途径。基于ckms分期的综合个性化护理模式对于减轻ckms相关并发症和提供高质量的综合癌症治疗是必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Atherosclerosis Reports 医学-

CiteScore

9.00

自引率

3.40%

发文量

审稿时长

6-12 weeks

期刊介绍： The aim of this journal is to systematically provide expert views on current basic science and clinical advances in the field of atherosclerosis and highlight the most important developments likely to transform the field of cardiovascular prevention, diagnosis, and treatment. We accomplish this aim by appointing major authorities to serve as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and papers published in the past year. We also provide supplementary reviews and commentaries from well-known figures in the field. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.